ImmunityBio Secures Macau SAR Authorization for ANKTIVA® in BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors ImmunityBio, today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special…
KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global…
Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the…
Bristol Myers Squibb Redefines First-Line Treatment Landscape in Classical Hodgkin Lymphoma with Expanded U.S. and EU Approvals for Opdivo® (nivolumab) Bristol Myers Squibb today announced that Opdivo® (nivolumab) has received approval for…
Novartis to Acquire Next-Generation Pan-Mutant PI3Kα Inhibitor, Enhancing Its Breast Cancer Treatment Pipeline Novartis has taken another significant step to strengthen its oncology pipeline, announcing a strategic agreement with Synnovation…
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of…
Biogen to Showcase Late-Breaking Phase 2 AMETHYST Data on Litifilimab in Cutaneous Lupus Erythematosus at the 2026 American Academy of Dermatology Annual Meeting Biogen Inc. has announced a series of…
TALZENNA in Combination with XTANDI Shows Marked Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Prostate Cancer Pfizer Inc. has announced compelling topline results from its Phase 3 TALAPRO-3…
Allergan Aesthetics Highlights Shifting Trends in Modern Aesthetic Care Through Global Survey and Enhanced Educational Initiatives Allergan Aesthetics, a division of AbbVie and a globally recognized leader in the field…
Novo Nordisk A/S: Wegovy® HD (7.2 mg) gains US approval, delivering 20.7% average weight reduction Novo Nordisk has reached another major milestone in the treatment of obesity, announcing that the…
Royalty Pharma Strengthens Executive Leadership Team to Support Strategic Growth and Investment Expansion Royalty Pharma plc has announced a significant expansion of its senior leadership team, underscoring the company’s continued…
Celltrion Launches AVTOZMA® (tocilizumab-anoh) Subcutaneous Formulation in the U.S. Market Celltrion has announced a significant milestone in its ongoing efforts to expand access to biologic therapies in the United States,…